Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA
Clin Cancer Res. 2011 17 (17): 5774-82

PMID: 21753154 · DOI:10.1158/1078-0432.CCR-11-0972

MeSH Terms (10)

Anilides Antineoplastic Agents Dose-Response Relationship, Drug Drug Administration Schedule Female Hedgehog Proteins Humans Male Neoplasms Pyridines

Connections (1)

This publication is referenced by other Labnodes entities: